UPC Ruling Protects Generic Drug Development: Zentiva Wins Marketing Authorization Case Against Boehringer Ingelheim
核心洞察
The Lisbon Local Division of the Unified Patent Court refused to grant Boehringer Ingelheim's preliminary injunction against Zentiva's marketing authorization for generic nintedanib (Ofev).
The court ruled that obtaining marketing authorization alone does not indicate imminent patent infringement, requiring assessment based on actual behavior and case facts.
This decision supports pharmaceutical companies' ability to prepare generic drugs for market entry without facing injunctions solely based on regulatory approvals.
The Unified Patent Court (UPC) has delivered a significant ruling that protects generic pharmaceutical companies' ability to obtain marketing authorization without facing immediate patent infringement claims, as demonstrated in a recent case involving Boehringer Ingelheim's idiopathic pulmonary fibrosis (搜索) drug Ofev.
Case Background
Zentiva, a Portuguese generics company, obtained marketing authorization for a generic version of Boehringer Ingelheim's nintedanib (Ofev) in August 2024. The original drug remains under patent protection until December 2025 and is covered by a Supplementary Protection Certificate (SPC) extending until April 2026. Despite this patent protection, Boehringer Ingelheim sought a preliminary injunction from the Lisbon Local Division, arguing that Zentiva's marketing authorization indicated an imminent risk of patent infringement.
Legal Precedent and Decision
The UPC's approach aligns with established precedent from the Düsseldorf Local Division. In the September 2024 case of Novartis and Genentech v Celltrion, the court established that marketing authorization alone is not relevant to assessing infringement risk. The Düsseldorf division stated that having market authorization does not indicate an intention to bring a product to market before patent protection expires.
On May 8, 2025, the Lisbon Local Division confirmed this position and refused to grant the injunction against Zentiva. The court emphasized that imminent infringement risk must be established based on the defendant's actual behavior and the specific facts of each case, rather than solely on regulatory approvals.
Industry Implications
This ruling addresses a critical aspect of pharmaceutical development timelines. Obtaining marketing authorization before patent expiration represents a standard and necessary preparation process for generic drug manufacturers. Companies routinely seek these approvals to ensure they can launch products immediately upon patent expiration, maximizing their competitive advantage in the generic market.
The UPC's decision demonstrates what the court describes as its "business minded nature" by protecting third parties' ability to achieve timely marketing authorization without facing injunction risks based solely on regulatory approvals. This approach balances patent holders' rights with the legitimate business preparations of generic manufacturers.
Strategic Considerations
The ruling provides important guidance for both patent holders and generic manufacturers operating under UPC jurisdiction. Patent holders seeking preliminary injunctions must demonstrate actual infringement risk through concrete evidence of market entry plans, rather than relying on regulatory milestones alone. Generic manufacturers, meanwhile, can pursue necessary regulatory approvals with greater confidence that such preparations will not automatically trigger patent enforcement actions.